Potential of alarmin-targeted bispecific and combination therapies in airway disease.

Front Allergy · 2025 · PMC12705614 · PMID 41409758

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

When assessed in the subgroup of patients who were former smokers, itepekimab demonstrated nominally significant reductions in acute COPD exacerbations compared with PBO and improvement in FEV1.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.